Apoe2 (Apolipoprotein E2) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Apoe2 (Apolipoprotein E2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Apolipoprotein E2 (APOE2) is the protective allele of the APOE gene, associated with significantly reduced risk of Alzheimer's disease (AD) compared to the common APOE3 allele. This allele provides a natural model for neuroprotection and has become a major focus of therapeutic research aiming to replicate its beneficial effects [1][2].
APOE2 differs from APOE3 (the most common allele) at two amino acid positions:
These cysteine residues form disulfide bridges, altering the protein's structure and function. APOE2 has:
| Feature | APOE2 | APOE3 | APOE4 |
|---|---|---|---|
| AD Risk | 50-60% reduced | Baseline | 3-4x increased |
| Aβ Clearance | Enhanced | Normal | Impaired |
| Lipid Binding | Reduced | Intermediate | Highest |
| LDLR Binding | Very Low (1-2%) | Normal (~50%) | Highest |
| Neuroinflammation | Anti-inflammatory | Neutral | Pro-inflammatory |
| Age of Onset | Delayed 2-3 yrs | Average | Earlier 5-10 yrs |
APOE2 has important cardiovascular implications [5]:
The neuroprotective effects of APOE2 appear to operate through multiple pathways:
APOE2's protective properties have inspired therapeutic strategies:
APOE2 carriers show:
Apoe2 (Apolipoprotein E2) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Apoe2 (Apolipoprotein E2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Reiman EM, et al. (2020). Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a community-based sample. Alzheimer's & Dementia, 16(12), 1653-1662. https://doi.org/10.1002/alz.12110
Serrano-Pozo A, et al. (2021). APOE2 and cognitive resilience. Nature Reviews Neurology, 17(2), 79-80. https://doi.org/10.1038/s41582-020-00438-9
Wolfe CM, et al. (2018). The role of APOE in the protective effects of lifestyle factors. Journal of Alzheimer's Disease, 62(3), 1117-1127. https://doi.org/10.3233/JAD-170713
Kim J, et al. (2014). Apolipoprotein E and lipid metabolism in Alzheimer's disease. Trends in Neurosciences, 37(10), 589-598. https://doi.org/10.1016/j.tins.2014.07.003
Mahley RW, et al. (2009). Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Journal of Molecular Medicine, 87(7), 653-664. https://doi.org/10.1007/s00109-009-0479-7
Flowers SA, et al. (2017). APOE2-associated hyperlipoproteinemia and accelerated atherosclerosis. Journal of Lipid Research, 58(7), 1364-1373. https://doi.org/10.1194/jlr.M075382
Tai LM, et al. (2015). The role of APOE in the pathogenesis of Alzheimer's disease. Neurobiology of Disease, 73, 254-267. https://doi.org/10.1016/j.nbd.2014.10.037